Neuroinflammation after traumatic brain injury (TBI) contributes to widespread cell death and tissue loss. Here, we evaluated sequential inflammatory response in the brain, as well as inflammation-induced changes in brain tryptophan metabolism over time, in a rabbit pediatric TBI model. On post-natal days 5–7 (P5–P7), New Zealand white rabbit littermates were randomized into three groups: naïve (no injury), sham (craniotomy alone), and TBI (controlled cortical impact). Animals were sacrificed at 6 h and 1, 3, 7, and 21 days post-injury for evaluating levels of pro- and anti-inflammatory cytokines, as well as the major components in the tryptophan-kynurenine pathway. We found that 1) pro- and anti-inflammatory cytokine levels in the brain injury area were differentially regulated in a time-dependent manner post-injury; 2) indoleamine 2,3 dioxygeenase 1 (IDO1) was upregulated around the injury area in TBI kits that persisted at 21 days post-injury; 3) mean length of serotonin-staining fibers was significantly reduced in the injured brain region in TBI kits for at least 21 days post-injury; and 4) kynurenine level significantly increased at 7 days post-injury. A significant decrease in serotonin/tryptophan ratio and melatonin/tryptophan ratio at 21 days post-injury was noted, suggesting that tryptophan metabolism is altered after TBI. A better understanding of the temporal evolution of immune responses and tryptophan metabolism during injury and repair after TBI is crucial for the development of novel therapeutic strategies targeting these pathways.
Get full access to this article
View all access options for this article.
References
1.
LangloisJ.A., Rutland-BrownW., and WaldM.M. (2006). The epidemiology and impact of traumatic brain injury: a brief overview. J. Head Trauma Rehabil., 21, 375–378.
2.
WilliamsonL.M., MorrisonA., and StoneD.H. (2002). Trends in head injury mortality among 0–14 year olds in Scotland (1986–95). J. Epidemiol. Community Health, 56, 285–288.
3.
RaimondiA., CocuzzaC., MusmannoG., and MattinaR. (1987). In vitro evaluation of CM 40876, a new third-generation cephalosporin. Chemioterapia, 6, 103–106.
4.
CiureaA.V., GorganM.R., TascuA., SanduA.M., and RizeaR.E. (2011). Traumatic brain injury in infants and toddlers, 0–3 years old. J. Med. Life, 4, 234–243.
5.
CarmodyD.P., DunnS.M., Boddie-WillisA.S., DeMarcoJ.K., and LewisM. (2004). A quantitative measure of myelination development in infants, using MR images. Neuroradiology, 46, 781–786.
6.
KoizumiH. (2004). The concept of ‘developing the brain’: a new natural science for learning and education. Brain Dev. 26, 434–441.
7.
HaynesR.L., BorensteinN.S., DesilvaT.M., FolkerthR.D., LiuL.G., VolpeJ.J., and KinneyH.C. (2005). Axonal development in the cerebral white matter of the human fetus and infant. J. Comp. Neurol., 484, 156–167.
8.
CosteffH., GroswasserZ., and GoldsteinR. (1990). Long-term follow-up review of 31 children with severe closed head trauma. J. Neurosurg., 73, 684–687.
9.
SalmondC.H., and SahakianB.J. (2005). Cognitive outcome in traumatic brain injury survivors. Curr. Opin. Crit. Care, 11, 111–116.
10.
KoskiniemiM., KyykkaT., NyboT., and JarhoL. (1995). Long-term outcome after severe brain injury in preschoolers is worse than expected. Arch. Pediatr. Adolesc. Med., 149, 249–254.
11.
DurkinM.S., OlsenS., BarlowB., VirellaA., and ConnollyE.S.Jr. (1998). The epidemiology of urban pediatric neurological trauma: evaluation of, and implications for, injury prevention programs. Neurosurgery, 42, 300–310.
12.
ButtramS.D., WisniewskiS.R., JacksonE.K., AdelsonP.D., FeldmanK., BayirH., BergerR.P., ClarkR.S., and KochanekP.M. (2007). Multiplex assessment of cytokine and chemokine levels in cerebrospinal fluid following severe pediatric traumatic brain injury: effects of moderate hypothermia. J. Neurotrauma, 24, 1707–1717.
13.
BayirH., KaganV.E., TyurinaY.Y., TyurinV., RuppelR.A., AdelsonP.D., GrahamS.H., JaneskoK., ClarkR.S., and KochanekP.M. (2002). Assessment of antioxidant reserves and oxidative stress in cerebrospinal fluid after severe traumatic brain injury in infants and children. Pediatr. Res., 51, 571–578.
14.
RuppelR.A., KochanekP.M., AdelsonP.D., RoseM.E., WisniewskiS.R., BellM.J., ClarkR.S., MarionD.W., and GrahamS.H. (2001). Excitatory amino acid concentrations in ventricular cerebrospinal fluid after severe traumatic brain injury in infants and children: the role of child abuse. J. Pediatr., 138, 18–25.
15.
BellM.J., KochanekP.M., DoughtyL.A., CarcilloJ.A., AdelsonP.D., ClarkR.S., WisniewskiS.R., WhalenM.J., and DeKoskyS.T. (1997). Interleukin-6 and interleukin-10 in cerebrospinal fluid after severe traumatic brain injury in children. J. Neurotrauma, 14, 451–457.
16.
BlockM.L., ZeccaL., and HongJ.S. (2007). Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature reviews. Neuroscience, 8, 57–69.
17.
KettenmannH., HanischU.K., NodaM. and VerkhratskyA. (2011). Physiology of microglia. Physiol. Rev., 91, 461–553.
18.
StreitW.J. (2002). Microglia and the response to brain injury. Ernst Schering Res. Found. Workshop, 39, 11–24.
19.
AarumJ., SandbergK., HaeberleinS.L., and PerssonM.A. (2003). Migration and differentiation of neural precursor cells can be directed by microglia. Proc. Natl. Acad. Sci. U. S. A., 100, 15983–15988.
20.
Michell-RobinsonM.A., TouilH., HealyL.M., OwenD.R., DurafourtB.A., Bar-OrA., AntelJ.P., and MooreC.S. (2015). Roles of microglia in brain development, tissue maintenance and repair. Brain, 138, 1138–1159.
21.
MossD.W., and BatesT.E. (2001). Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci., 13, 529–538.
22.
SawadaM., KondoN., SuzumuraA., and MarunouchiT. (1989). Production of tumor necrosis factor-alpha by microglia and astrocytes in culture. Brain Res. 491, 394–397.
23.
BanatiR.B., GehrmannJ., SchubertP., and KreutzbergG.W. (1993). Cytotoxicity of microglia. Glia, 7, 111–118.
24.
BlightA.R., CohenT.I., SaitoK., and HeyesM.P. (1995). Quinolinic acid accumulation and functional deficits following experimental spinal cord injury. Brain, 118, Pt. 3, 735–752.
25.
HeyesM.P., SaitoK., CrowleyJ.S., DavisL.E., DemitrackM.A., DerM., DillingL.A., EliaJ., KruesiM.J., LacknerA., LarsenS.A., LeeK., LeonardH.L., MarkeyS.P., MartinA., MilsteinS., MouradianM.M., PranzatelliM.R., QuearryB.J., SalazarA., SmithM., StraussS.E., SunderlandT., SwedoS.W., and TourtellotteW.W. (1992). Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain, 115, Pt. 5, 1249–1273.
26.
RasouliJ., LekhrajR., OzbalikM., LalezariP., and CasperD. (2011). Brain-spleen inflammatory coupling: a literature review. Einstein J. Biol. Med., 27, 74–77.
27.
VahidyF.S., ParshaK.N., RahbarM.H., LeeM., BuiT.T., NguyenC., BarretoA.D., BambhroliyaA.B., SahotaP., YangB., AronowskiJ., and SavitzS.I. (2016). Acute splenic responses in patients with ischemic stroke and intracerebral hemorrhage. J. Cereb. Blood Flow Metab., 36, 1012–1021.
28.
Portera-CailliauC., PriceD.L., and MartinL.J. (1997). Non-NMDA and NMDA receptor-mediated excitotoxic neuronal deaths in adult brain are morphologically distinct: further evidence for an apoptosis-necrosis continuum. J. Comp. Neurol., 378, 88–104.
29.
SuselZ., EngberT.M., KuoS., and ChaseT.N. (1991). Prolonged infusion of quinolinic acid into rat striatum as an excitotoxic model of neurodegenerative disease. Neurosci. Lett., 121, 234–238.
30.
YanE.B., FrugierT., LimC.K., HengB., SundaramG., TanM., RosenfeldJ.V., WalkerD.W., GuilleminG.J., and Morganti-KossmannM.C. (2015). Activation of the kynurenine pathway and increased production of the excitotoxin quinolinic acid following traumatic brain injury in humans. J. Neuroinflammation, 12, 110.
31.
SinzE.H., KochanekP.M., HeyesM.P., WisniewskiS.R., BellM.J., ClarkR.S., DeKoskyS.T., BlightA.R., and MarionD.W. (1998). Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J. Cereb. Blood Flow Metab., 18, 610–615.
32.
BellM.J., KochanekP.M., HeyesM.P., WisniewskiS.R., SinzE.H., ClarkR.S., BlightA.R., MarionD.W., and AdelsonP.D. (1999). Quinolinic acid in the cerebrospinal fluid of children after traumatic brain injury. Crit. Care Med., 27, 493–497.
33.
BergerR.P., HeyesM.P., WisniewskiS.R., AdelsonP.D., ThomasN., and KochanekP.M. (2004). Assessment of the macrophage marker quinolinic acid in cerebrospinal fluid after pediatric traumatic brain injury: insight into the timing and severity of injury in child abuse. J. Neurotrauma, 21, 1123–1130.
34.
MeierT.B., SavitzJ., SinghR., TeagueT.K., and BellgowanP.S. (2016). Smaller dentate gyrus and CA2 and CA3 volumes are associated with kynurenine metabolites in collegiate football athletes. J. Neurotrauma, 33, 1349–1357.
35.
BalasingamV., and YongV.W. (1996). Attenuation of astroglial reactivity by interleukin-10. J. Neurosci., 16, 2945–2955.
36.
HolminS., SchallingM., HojebergB., NordqvistA.C., SkeftrunaA.K., and MathiesenT. (1997). Delayed cytokine expression in rat brain following experimental contusion. J. Neurosurg., 86, 493–504.
37.
SarkhoshK., TredgetE.E., KaramiA., UludagH., IwashinaT., KilaniR.T., and GhaharyA. (2003). Immune cell proliferation is suppressed by the interferon-gamma-induced indoleamine 2,3-dioxygenase expression of fibroblasts populated in collagen gel (FPCG). J. Cell. Biochem., 90, 206–217.
38.
MeiselR., ZibertA., LaryeaM., GobelU., DaubenerW., and DillooD. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood, 103, 4619–4621.
39.
GuilleminG.J., BrewB.J., NoonanC.E., TakikawaO., and CullenK.M. (2005). Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus. Neuropathol. Appl. Neurobiol., 31, 395–404.
40.
RichardD.M., DawesM.A., MathiasC.W., AchesonA., Hill-KapturczakN., and DoughertyD.M. (2009). L-tryptophan: basic metabolic functions, behavioral research and therapeutic indications. Int. J. Tryptophan Res., 2, 45–60.
41.
LevinH., and KrausM.F. (1994). The frontal lobes and traumatic brain injury. J. Neuropsychiatry Clin. Neurosci., 6, 443–454.
42.
FannJ.R., HartT., and SchomerK.G. (2009). Treatment for depression after traumatic brain injury: a systematic review. J. Neurotrauma, 26, 2383–2402.
43.
YueJ.K., BurkeJ.F., UpadhyayulaP.S., WinklerE.A., DengH., RobinsonC.K., PirracchioR., SuenC.G., SharmaS., FergusonA.R., NgwenyaL.B., SteinM.B., ManleyG.T., and TaraporeP.E. (2017). Selective serotonin reuptake inhibitors for treating neurocognitive and neuropsychiatric disorders following traumatic brain injury: an evaluation of current evidence. Brain Sci. 7, E93.
44.
JorgeR.E., AcionL., BurinD.I., and RobinsonR.G. (2016). Sertraline for preventing mood disorders following traumatic brain injury: a randomized clinical trial. JAMA Psychiatry, 73, 1041–1047.
45.
BrummelteS., Mc GlanaghyE., BonninA., and OberlanderT.F. (2017). Developmental changes in serotonin signaling: implications for early brain function, behavior and adaptation. Neuroscience, 342, 212–231.
46.
BassaniT.B., GradowskiR.W., ZaminelliT., BarbieroJ.K., SantiagoR.M., BoschenS.L., da CunhaC., LimaM.M., AndreatiniR., and VitalM.A. (2014). Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson's disease model in rats. Brain Res. 1593, 95–105.
47.
BendzL.M., and ScatesA.C. (2010). Melatonin treatment for insomnia in pediatric patients with attention-deficit/hyperactivity disorder. Ann. Pharmacother., 44, 185–191.
48.
RossignolD.A., and FryeR.E. (2014). Melatonin in autism spectrum disorders. Curr. Clin. Pharmacol., 9, 326–334.
49.
MillerE., MorelA., SasoL., and SalukJ. (2015). Melatonin redox activity. Its potential clinical application in neurodegenerative disorders. Curr. Top. Med. Chem., 15, 163–169.
50.
ElkhayatH.A., HassaneinS.M., TomoumH.Y., Abd-ElhamidI.A., AsaadT., and ElwakkadA.S. (2010). Melatonin and sleep-related problems in children with intractable epilepsy. Pediatr. Neurol., 42, 249–254.
51.
DamianiJ.M., SweetB.V., and SohoniP. (2014). Melatonin: an option for managing sleep disorders in children with autism spectrum disorder. Am. J. Health Syst. Pharm., 71, 95–101.
52.
ZhangZ., SaraswatiM., KoehlerR.C., RobertsonC., and KannanS. (2015). A new rabbit model of pediatric traumatic brain injury. J. Neurotrauma, 32, 1369–1379.
53.
GelmanA., and HillJ. (2007). Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press: Cambridge, UK; New York, NY.
54.
PrattO.E. (1979). Kinetics of tryptophan transport across the blood-brain barrier. J. Neural Transmission. J. Neural Transm. Suppl. (15), 29–42.
55.
PardridgeW.M. (1998). Blood-brain barrier carrier-mediated transport and brain metabolism of amino acids. Neurochem. Res., 23, 635–644.
56.
KumarA., Alvarez-CrodaD.M., StoicaB.A., FadenA.I., and LoaneD.J. (2016). Microglial/macrophage polarization dynamics following traumatic brain injury. J. Neurotrauma, 33, 1732–1750.
57.
ShohamiE., NovikovM., BassR., YaminA., and GallilyR. (1994). Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J. Cereb. Blood Flow Metab., 14, 615–619.
58.
FanL., YoungP.R., BaroneF.C., FeuersteinG.Z., SmithD.H., and McIntoshT.K. (1996). Experimental brain injury induces differential expression of tumor necrosis factor-alpha mRNA in the CNS. Brain Res. Mol. Brain Res., 36, 287–291.
59.
WilliamsA.J., WeiH.H., DaveJ.R., and TortellaF.C. (2007). Acute and delayed neuroinflammatory response following experimental penetrating ballistic brain injury in the rat. J. Neuroinflammation, 4, 17.
60.
DalgardC.L., ColeJ.T., KeanW.S., LuckyJ.J., SukumarG., McMullenD.C., PollardH.B., and WatsonW.D. (2012). The cytokine temporal profile in rat cortex after controlled cortical impact. Front. Mol. Neurosci., 5, 6.
61.
KnoblachS.M., and FadenA.I. (1998). Interleukin-10 improves outcome and alters proinflammatory cytokine expression after experimental traumatic brain injury. Exp. Neurol., 153, 143–151.
62.
SheblF.M., PintoL.A., Garcia-PineresA., LempickiR., WilliamsM., HarroC., and HildesheimA. (2010). Comparison of mRNA and protein measures of cytokines following vaccination with human papillomavirus-16 L1 virus-like particles. Cancer Epidemiol. Biomarkers Prev., 19, 978–981.
63.
MehraA., LeeK.H., and HatzimanikatisV. (2003). Insights into the relation between mRNA and protein expression patterns: I. Theoretical considerations. Biotechnol. Bioeng., 84, 822–833.
64.
NieL., WuG., and ZhangW. (2006). Correlation of mRNA expression and protein abundance affected by multiple sequence features related to translational efficiency in Desulfovibrio vulgaris: a quantitative analysis. Genetics, 174, 2229–2243.
65.
KozakM. (2007). Some thoughts about translational regulation: forward and backward glances. J. Cell. Biochem., 102, 280–290.
66.
DinarelloC.A., SimonA., and van der MeerJ.W. (2012). Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov., 11, 633–652.
67.
BoutinH., LeFeuvreR.A., HoraiR., AsanoM., IwakuraY., and RothwellN.J. (2001). Role of IL-1alpha and IL-1beta in ischemic brain damage. J. Neurosci., 21, 5528–5534.
68.
LuK.T., WangY.W., YangJ.T., YangY.L., and ChenH.I. (2005). Effect of interleukin-1 on traumatic brain injury-induced damage to hippocampal neurons. J. Neurotrauma, 22, 885–895.
69.
FrugierT., Morganti-KossmannM.C., O'ReillyD., and McLeanC.A. (2010). In situ detection of inflammatory mediators in post mortem human brain tissue after traumatic injury. J. Neurotrauma, 27, 497–507.
70.
HayakataT., ShiozakiT., TasakiO., IkegawaH., InoueY., ToshiyukiF., HosotuboH., KiekoF., YamashitaT., TanakaH., ShimazuT., and SugimotoH. (2004). Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. Shock, 22, 102–107.
71.
ChiarettiA., GenoveseO., AloeL., AntonelliA., PiastraM., PolidoriG., and Di RoccoC. (2005). Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv. Syst., 21, 185–193; discussion, 194.
72.
SemenzatoG. (1990). Tumour necrosis factor: a cytokine with multiple biological activities. Br. J. Cancer, 61, 354–361.
73.
SuzukiT., HideI., IdoK., KohsakaS., InoueK., and NakataY. (2004). Production and release of neuroprotective tumor necrosis factor by P2X7 receptor-activated microglia. The J. Neurosci., 24, 1–7.
74.
HideI., TanakaM., InoueA., NakajimaK., KohsakaS., InoueK., and NakataY. (2000). Extracellular ATP triggers tumor necrosis factor-alpha release from rat microglia. J. Neurochem., 75, 965–972.
75.
BrennerT., YaminA., AbramskyO., and GallilyR. (1993). Stimulation of tumor necrosis factor-alpha production by mycoplasmas and inhibition by dexamethasone in cultured astrocytes. Brain Res. 608, 273–279.
76.
BenvenisteE.N., TangL.P., and LawR.M. (1995). Differential regulation of astrocyte TNF-alpha expression by the cytokines TGF-beta, IL-6 and IL-10. Int. J. Dev. Neurosci., 13, 341–349.
77.
ReidT.R., TortiF.M., and RingoldG.M. (1989). Evidence for two mechanisms by which tumor necrosis factor kills cells. J. Biol. Chem., 264, 4583–4589.
78.
GoodmanJ.C., RobertsonC.S., GrossmanR.G., and NarayanR.K. (1990). Elevation of tumor necrosis factor in head injury. J. Neuroimmunol., 30, 213–217.
79.
RossS.A., HallidayM.I., CampbellG.C., ByrnesD.P., and RowlandsB.J. (1994). The presence of tumour necrosis factor in CSF and plasma after severe head injury. Br. J. Neurosurg., 8, 419–425.
80.
ShiozakiT., HayakataT., TasakiO., HosotuboH., FuijitaK., MouriT., TajimaG., KajinoK., NakaeH., TanakaH., ShimazuT., and SugimotoH. (2005). Cerebrospinal fluid concentrations of anti-inflammatory mediators in early-phase severe traumatic brain injury. Shock, 23, 406–410.
81.
SteinD.M., LindellA., MurdockK.R., KuferaJ.A., MenakerJ., KeledjianK., BochicchioG.V., AarabiB., and ScaleaT.M. (2011). Relationship of serum and cerebrospinal fluid biomarkers with intracranial hypertension and cerebral hypoperfusion after severe traumatic brain injury. J. Trauma, 70, 1096–1103.
82.
BermpohlD., YouZ., LoE.H., KimH.H., and WhalenM.J. (2007). TNF alpha and Fas mediate tissue damage and functional outcome after traumatic brain injury in mice. J. Cereb. Blood Flow Metab., 27, 1806–1818.
83.
ScherbelU., RaghupathiR., NakamuraM., SaatmanK.E., TrojanowskiJ.Q., NeugebauerE., MarinoM.W., and McIntoshT.K. (1999). Differential acute and chronic responses of tumor necrosis factor-deficient mice to experimental brain injury. Proc. Natl. Acad. Sci. U. S. A., 96, 8721–8726.
84.
SullivanP.G., Bruce-KellerA.J., RabchevskyA.G., ChristakosS., ClairD.K., MattsonM.P., and ScheffS.W. (1999). Exacerbation of damage and altered NF-kappaB activation in mice lacking tumor necrosis factor receptors after traumatic brain injury. J. Neurosci., 19, 6248–6256.
85.
CouperK.N., BlountD.G., and RileyE.M. (2008). IL-10: the master regulator of immunity to infection. J. Immunol., 180, 5771–5777.
86.
MooreK.W., de Waal MalefytR., CoffmanR.L., and O'GarraA. (2001). Interleukin-10 and the interleukin-10 receptor. Ann. Rev. Immunol., 19, 683–765.
87.
KammK., VanderkolkW., LawrenceC., JonkerM., and DavisA.T. (2006). The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J. Trauma, 60, 152–157.
88.
SawadaM., SuzumuraA., HosoyaH., MarunouchiT., and NagatsuT. (1999). Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia. J. Neurochem., 72, 1466–1471.
89.
Lobo-SilvaD., CarricheG.M., CastroA.G., RoqueS., and SaraivaM. (2016). Balancing the immune response in the brain: IL-10 and its regulation. J. Neuroinflammation, 13, 297.
90.
CsukaE., Morganti-KossmannM.C., LenzlingerP.M., JollerH., TrentzO., and KossmannT. (1999). IL-10 levels in cerebrospinal fluid and serum of patients with severe traumatic brain injury: relationship to IL-6, TNF-alpha, TGF-beta1 and blood-brain barrier function. J. Neuroimmunol., 101, 211–221.
91.
MaierB., SchwerdtfegerK., MautesA., HolandaM., MullerM., SteudelW.I., and MarziI. (2001). Differential release of interleukines 6, 8, and 10 in cerebrospinal fluid and plasma after traumatic brain injury. Shock, 15, 421–426.
92.
ConnorT.J., StarrN., O'SullivanJ.B., and HarkinA. (2008). Induction of indolamine 2,3-dioxygenase and kynurenine 3-monooxygenase in rat brain following a systemic inflammatory challenge: a role for IFN-gamma?. Neurosci. Lett., 441, 29–34.
93.
FujigakiH., SaitoK., FujigakiS., TakemuraM., SudoK., IshiguroH., and SeishimaM. (2006). The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J. Biochem., 139, 655–662.
94.
ZunszainP.A., AnackerC., CattaneoA., ChoudhuryS., MusaelyanK., MyintA.M., ThuretS., PriceJ., and ParianteC.M. (2012). Interleukin-1beta: a new regulator of the kynurenine pathway affecting human hippocampal neurogenesis. Neuropsychopharmacology, 37, 939–949.
95.
BhutiaY.D., BabuE., and GanapathyV. (2015). Interferon-gamma induces a tryptophan-selective amino acid transporter in human colonic epithelial cells and mouse dendritic cells. Biochim. Biophys. Acta, 1848, 453–462.
96.
ReganT., GillA.C., ClohiseyS.M., BarnettM.W., ParianteC.M., HarrisonN.A., ConsortiumM.R.C.I., HumeD.A., BullmoreE.T., and FreemanT.C. (2018). Effects of anti-inflammatory drugs on the expression of tryptophan-metabolism genes by human macrophages. J. Leukoc. Biol., 103, 681–692.
97.
Vasquez-VivarJ., ShiZ., LuoK., ThirugnanamK., and TanS. (2017). Tetrahydrobiopterin in antenatal brain hypoxia-ischemia-induced motor impairments and cerebral palsy. Redox Biol. 13, 594–599.
98.
TangL.L., and ZhengJ.S. (2011). Effects of tetrahydrobiopterin on cerebral infarction after transient focal ischemia in rats. Neurol. Res., 33, 1064–1067.
99.
TsuchiyamaR., SozenT., TitovaE., ZhangJ.H., and TangJ. (2010). The effects of tetrahydrobiopterin on intracerebral hemorrhage-induced brain injury in mice. Acta Neurochir. Suppl., 106, 155–157.
100.
OuelletM.C., Beaulieu-BonneauS., and MorinC.M. (2015). Sleep-wake disturbances after traumatic brain injury. Lancet Neurol. 14, 746–757.
101.
LauderJ.M., WallaceJ.A., and KrebsH. (1981). Roles for serotonin in neuroembryogenesis. Adv. Exp. Med. Biol., 133, 477–506.
102.
GasparP., CasesO., and MaroteauxL. (2003). The developmental role of serotonin: news from mouse molecular genetics. Nat. Rev. Neurosci., 4, 1002–1012.
103.
SodhiM.S., and Sanders-BushE. (2004). Serotonin and brain development. Int. Rev. Neurobiol., 59, 111–174.
104.
DaubertE.A., and CondronB.G. (2010). Serotonin: a regulator of neuronal morphology and circuitry. Trends Neurosci. 33, 424–434.
105.
TrakhtenbergE.F., and GoldbergJ.L. (2012). The role of serotonin in axon and dendrite growth. Int. Rev. Neurobiol., 106, 105–126.
106.
MiceliS., NegwerM., van EijsF., KalkhovenC., van LieropI., HombergJ., and SchubertD. (2013). High serotonin levels during brain development alter the structural input-output connectivity of neural networks in the rat somatosensory layer IV. Front. Cell. Neurosci., 7, 88.
107.
Narboux-NemeN., PavoneL.M., AvalloneL., ZhuangX., and GasparP. (2008). Serotonin transporter transgenic (SERTcre) mouse line reveals developmental targets of serotonin specific reuptake inhibitors (SSRIs). Neuropharmacology, 55, 994–1005.
108.
D'AmatoR.J., BlueM.E., LargentB.L., LynchD.R., LedbetterD.J., MolliverM.E., and SnyderS.H. (1987). Ontogeny of the serotonergic projection to rat neocortex: transient expression of a dense innervation to primary sensory areas. Proc. Natl. Acad. Sci. U. S. A., 84, 4322–4326.
109.
LebrandC., CasesO., AdelbrechtC., DoyeA., AlvarezC., El MestikawyS., SeifI., and GasparP. (1996). Transient uptake and storage of serotonin in developing thalamic neurons. Neuron, 17, 823–835.
110.
Bennett-ClarkeC.A., ChiaiaN.L., and RhoadesR.W. (1997). Contributions of raphe-cortical and thalamocortical axons to the transient somatotopic pattern of serotonin immunoreactivity in rat cortex. Somatosens Mot Res, 14, 27–33.
111.
MaddaloniG., BerteroA., PratelliM., BarsottiN., BoonstraA., GiorgiA., MigliariniS., and PasqualettiM. (2017). Development of serotonergic fibers in the post-natal mouse brain. Front. Cell. Neurosci., 11, 202.
112.
McKeeA.C., and DaneshvarD.H. (2015). The neuropathology of traumatic brain injury. Handb. Clin. Neurol., 127, 45–66.
113.
SmithD.H., HicksR., and PovlishockJ.T. (2013). Therapy development for diffuse axonal injury. J. Neurotrauma, 30, 307–323.
114.
CholletF., TardyJ., AlbucherJ.F., ThalamasC., BerardE., LamyC., BejotY., DeltourS., JaillardA., NiclotP., GuillonB., MoulinT., MarqueP., ParienteJ., ArnaudC., and LoubinouxI. (2011). Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 10, 123–130.
115.
SiepmannT., PenzlinA.I., KepplingerJ., IlligensB.M., WeidnerK., ReichmannH. and BarlinnK. (2015). Selective serotonin reuptake inhibitors to improve outcome in acute ischemic stroke: possible mechanisms and clinical evidence. Brain Behav. 5, e00373.
116.
WuH., ShaoA., ZhaoM., ChenS., YuJ., ZhouJ., LiangF., ShiL., DixonB.J., WangZ., LingC., HongY., and ZhangJ. (2016). Melatonin attenuates neuronal apoptosis through up-regulation of K(+) -Cl(-) cotransporter KCC2 expression following traumatic brain injury in rats. J. Pineal Res., 61, 241–250.
117.
GrimaN.A., RajaratnamS.M.W., MansfieldD., SlettenT.L., SpitzG., and PonsfordJ.L. (2018). Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial. BMC Med. 16, 8.
118.
LorenteL., MartinM.M., Abreu-GonzalezP., Perez-CejasA., RamosL., ArguesoM., Sole-ViolanJ., CaceresJ.J., JimenezA., and Garcia-MarinV. (2017). Serum melatonin levels in survivor and non-survivor patients with traumatic brain injury. BMC Neurol. 17, 138.
119.
SeifmanM.A., GomesK., NguyenP.N., BaileyM., RosenfeldJ.V., CooperD.J., and Morganti-KossmannM.C. (2014). Measurement of serum melatonin in intensive care unit patients: changes in traumatic brain injury, trauma, and medical conditions. Front. Neurol., 5, 237.
120.
MarsegliaL., D'AngeloG., MantiS., RulliI., SalvoV., BuonocoreG., ReiterR.J., and GittoE. (2017). Melatonin secretion is increased in children with severe traumatic brain injury. Int. J. Mol. Sci., 18, 1053.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
